logo
PricingOpen Demat Account at ₹0 AMCBecome a PartnerCustomer ServiceDhan SupportDhan Blog
fuzz
Logo
MadeForTrade CommunityIndicator by Dhan
Home
InvestmentsIPOAnthem Biosciences IPO

Anthem Biosciences IPO

Mainboard

Open Date

14 Jul 2025

Close Date

16 Jul 2025

Min Investment

₹ 14,820

Lot Size

26

Issue Size

₹ 3584.50 Cr

Price Range

₹ 540 - ₹ 570

Subscribed

27.01 x
status

This IPO is now Live.

Click here for live price
IPO Timeline
check
IPO Offer Start
14 Jul 2025
check
IPO Offer Ends
16 Jul 2025
check
Allotment Finalisation
17 Jul 2025
check
Refund Initialisation
18 Jul 2025
check
Non-Institutional Buyers (sHNI)
18 Jul 2025
check
Listing of Shares
21 Jul 2025
IPO Subscription Details as on 6 Apr 2026, 04:33 AM
Qualified Instituational Buyers (QiB)
76.36 x
Retail
2.25 x
Employees
2.41 x
Total
27.01 x
Non-Institutional Buyer (bHNI)
23.16 x
Non-Institutional Buyer (sHNI)
11.89 x
Note: This information is provided for general guidance only. Dates may be subject to change.
border
About the Company
The company is a comprehensive one-stop service provider across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics. It is the fastest growing Indian CRDMO (Contract Research, Development and Manufacturing Organization). The company offers technologically advanced solutions and has a differentiated business model catering to the needs of small pharmaceutical and emerging biotech companies. It maintains long-standing relationships with a large, diversified and loyal customer base. The company has a wide specialty ingredients portfolio, focusing on niche specialty fermentation-based products, probiotics, enzymes, nutritional actives, and vitamin analogues. It operates with a fully built-out automated manufacturing infrastructure and has a consistent regulatory compliance track record. The company has demonstrated industry-leading growth, profitability and capital efficiency, and is supported by a professional and experienced leadership team with a qualified scientific talent pool.
rocket

Founded In

2006

rocket

CEO

Ajay Bhardwaj

Financials of Anthem Biosciences IPO

Income Statement
Balance Sheet
Cash Flows
Total Income
Total Expenses
Total Profit
Key Performance IndicatorsSep 2023Mar 2024Sep 2024
Operating Revenue5,885.8814,193.708,635.50
Other Income345.85636.99473.00
Total Income
6,231.7314,830.699,108.50
Total Expenses
4,144.8110,057.515,933.41
Profit Before Tax2,086.934,773.183,175.09
Total Profit
1,571.043,673.102,443.06

All figures are in lakhs (₹)

border

Utilisation of Proceeds

All figures are in lakhs (₹)

PurposeAmount
Funds raised may be used for general corporate purposes, which could include working capital, capital expenditures, repayment of debt, or other corporate uses.-
border
  • Comprehensive one-stop CRDMO service capabilities: The company offers integrated services across the drug lifecycle for both small molecules and biologics, from discovery to commercial manufacturing. It is one of the few Indian companies with capabilities across all three segments of drug discovery, development and manufacturing for both NCEs and NBEs.
  • Innovation-focused approach with advanced technological capabilities: The company has developed capabilities across various modalities like RNAi, ADC, peptides, lipids and oligonucleotides. It offers the broadest range of technology capabilities for drug development among Indian peers, including biotransformation, flow chemistry, and fermentation-based manufacturing.
  • Differentiated business model catering to emerging biotech companies: The company focuses on serving small pharmaceutical and emerging biotech companies through FFS contracts, providing end-to-end services from discovery to commercialization. This allows it to develop long-term relationships and grow with these customers.
  • Long-standing relationships with diverse customer base: The company has over 425 customers across 44+ countries, including large pharmaceutical companies. Its top 10 customers have an average relationship length of 11.6 years, demonstrating customer loyalty and ability to provide services across the drug lifecycle.
  • Specialty ingredients portfolio with large market opportunity: The company manufactures complex specialty ingredients like probiotics, enzymes, peptides and biosimilars, leveraging its technological capabilities. This provides a complementary revenue stream targeting both regulated and semi-regulated markets.
  • Fully built-out automated manufacturing infrastructure: The company has 3 manufacturing facilities with cGMP compliance and regulatory approvals from agencies like USFDA, TGA, ANVISA and PMDA. Its facilities are highly automated with features like DCS to ensure quality, efficiency and safety.
  • Industry-leading growth, profitability and capital efficiency: The company achieved the highest revenue growth of 34.29% from FY23 to FY24 among Indian and global peers. It has industry-leading EBITDA margins and capital efficiency metrics like ROCE and ROE compared to peers.
  • Experienced leadership and qualified scientific talent: The company is led by an experienced founding team and senior management with 25+ years of industry experience each. It has a team of over 1,500 qualified scientific staff, including 35 PhDs and 1,100+ Masters degree holders.

Open IPOs for Subscription

No Open IPOs

Stay tuned, there will be more IPOs listing soon!


fuzz

Listed IPOs

No Listed IPOs

Stay tuned, there will be more IPOs listing soon!


Invest & Trade with a Trading
Platform That's #MadeForTrade

Open your Dhan Account in minutes!
border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors